Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 29 • 2019 ACR/ARP Annual Meeting
Therapeutic Anti-TNF Biologic Agents Exhibit Functional Differences in Blocking TNF-induced Effects on Human Monocytes In Vitro
Bohdan Harvey¹ and Zehra Kaymakcalan ¹, ¹AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Therapeutic anti-TNF biologic agents can be distinct in their structure and/or in their binding to TNF. Whether these differences affect the functional properties of…
Abstract Number: 112 • 2019 ACR/ARP Annual Meeting
Impact of Interleukin-9 on the Immune Suppressive Functions of Regulatory T Cells in Rheumatoid Arthritis
Sushmita Chakraborty ¹, Ranjan Gupta ², Rinkee Kumari ¹ and Dipendra Kumar Mitra¹, ¹All India Institute of Medical Sciences, Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: An important component of the immune tolerance is regulatory T cells (Tregs), which prevents autoimmunity and restrains inflammatory reactions. In Rheumatoid Arthritis (RA), there…
Abstract Number: 194 • 2019 ACR/ARP Annual Meeting
Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data
Fredrik Johansson¹, Jamie Collins ², Sara Gale ³, Hongshu Guan ⁴, Seoyoung C. Kim ⁵, Elena Losina ⁶, David Sontag ¹, Jacklyn Stratton ⁴, Huong Trinh ³, Jeffrey Greenberg ⁷ and Daniel Solomon ⁸, ¹MIT, Cambridge, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Genentech, San Francisco, CA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁸Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Predicting remission in rheumatoid arthritis (RA) is an important goal for tailoring therapy. Tocilizumab (TCZ) has been found in randomized controlled trials (RCT) to…
Abstract Number: 296 • 2019 ACR/ARP Annual Meeting
Prevalence of Elbow Arthritis in Patients with Rheumatoid Arthritis: A Prospective Ultrasound Study
Diana Vossen ¹, Valentin Schaefer², Florian Recker ³, Isabelle Geffken ⁴, Eva Matuschek ⁵ and Wolfgang Hartung ⁶, ¹Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, ²Medical Clinic III , Rheumatology und clinical Immunology, University Hospital Bonn, Bonn, Germany, ³1. Medical Clinic III , Rheumatology und clinical Immunology, University Hospital Bonn and 2. Department for Obstetrics and Gynecology, University Hospital Bonn, Bonn, Germany, ⁴Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St.Elisabeth Hospital, Düsseldorf, Germany, ⁵Department for Internal Medicine, Dreifaltigkeits-Krankenhaus Wesseling, bonn, Germany, ⁶Rheumatology und clinical Immunology, Asklepios Klinik, 93077 Bad Abbach, Bad Abbach, Germany
Background/Purpose: Musculoskeletal ultrasound is an important imaging method in the diagnosis of arthritis, especially rheumatoid arthritis (RA). The prevalence of elbow joint arthritis in RA…
Abstract Number: 450 • 2019 ACR/ARP Annual Meeting
ACPA-positive versus ACPA-negative Rheumatoid Arthritis: Two Distinct Erosive Disease Entities on Radiography and Ultrasonography
Julien Grosse¹, Edem Allado ¹, Camille Roux ¹, Audrey Pierreisnard ², Marion Couderc ³, Isabelle Clerc-Urmès ¹, Thomas Remen ¹, Eliane Albuisson ⁴, Marcelo De Carvalho ¹, Isabelle Chary-Valckenaere ⁴ and Damien Loeuille ⁵, ¹Centre Hospitalier Universitaire de Nancy, Nancy, France, ²APHP, Paris, France, ³CHU G.Montpied, Clermont Ferrand, France, ⁴Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ⁵Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France
Background/Purpose: Several studies have shown that ACPA-positive (ACPA+) patients were more likely to develop erosive disease on radiography (RX) than ACPA-negative (ACPA-) patients, but it…
Abstract Number: 477 • 2019 ACR/ARP Annual Meeting
Inflammation but Also Pain and Function, and Psychological Impact Is Related to Non-Acceptable Status in Patients with Rheumatoid Arthritis: A Factorial Analysis in 643 Patients
Catia Duarte¹, Eduardo Santos ², Eirik Kristianslund ³, Turid Heiberg ⁴, Maarten de Wit ⁵, Maxime Dougados ⁶, Tore Kvien ⁷, Laure Gossec ⁸ and Jose Pereira da Silva ⁹, ¹Department of Rheumatology, Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal, ²Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ⁴Department for Research and Education, Oslo University Hospital, Oslo, Norway, ⁵Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁶Cochin Hospital, Paris, France, ⁷Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁸Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁹Centro Hospitalar Universitario de Coimbra, Coimbra, Coimbra, Portugal
Background/Purpose: Patient Acceptable Symptom State (PASS) represents the maximum level of symptom intensity that a patient considers acceptable. Control of disease activity is associated with the…
Abstract Number: 528 • 2019 ACR/ARP Annual Meeting
Assessment of Bone and Cartilage Turnover Markers Following Treatment with Repository Corticotropin Injection in Patients with Persistently Active Rheumatoid Arthritis
Roy Fleischmann¹, Daniel Furst ², Erin Connolly-Strong ³, Jingyu Liu ³, Julie Zhu ³ and Richard Brasington ⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of California, Los Angeles, CA, ³Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, ⁴Washington University School of Medicine in St Louis, St Louis, MO
Background/Purpose: Persistently active rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation and bone loss.1 Although short-term administration of corticosteroids (CSs) is recommended…
Abstract Number: 833 • 2019 ACR/ARP Annual Meeting
Effect of a Mobile App to Monitor Patient Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial
Yvonne Lee¹, Fengxin Lu ², Joshua Colls ², Meredith Murray ², Dong Suh ², Jing Song ³, Julia (Jungwha) Lee ⁴, Dorothy Dunlop ⁴ and Daniel Solomon ⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, ²Brigham and Women's Hospital, Boston, MA, ³Northwestern University Feinberg School of Medicine, Worthington, OH, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Treat to target (TTT) is an effective strategy to improve outcomes in rheumatoid arthritis (RA). However, barriers to TTT include frequent clinic visits, poor…
Abstract Number: 932 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi ², Hisashi Yamanaka ³, Toshihiro Nanki ⁴, Hisanori Umehara ⁵, Nobuyuki Yasuda ⁶, Fumitoshi Tago ⁷, Yasumi Kitahara ⁸, Makoto Kawakubo ⁷, Kentaro Torii ⁸, Seiichiro Hojo ⁸, Tetsu Kawano ⁶ and Toshio Imai ⁶, ¹University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Sanno Medical Center, Minato-ku, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Nagahama City Hospital / Division of Rheumatology and Immunology, Nagahama, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan, ⁷Eisai Co., Ltd., Tokyo, Japan, ⁸Eisai Co., Ltd., Bunkyo-ku, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 1151 • 2019 ACR/ARP Annual Meeting
The Impact of Gender on Time to Rheumatoid Arthritis Classification
Caitrin Coffey¹, John Davis ¹ and Cynthia Crowson ², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester
Background/Purpose: Rheumatoid arthritis differs between genders with regard to comorbidities, extra-articular manifestations, core measures of disease activity, and treatment response. Gender has not previously been…
Abstract Number: 1341 • 2019 ACR/ARP Annual Meeting
Impact of Tocilizumab on Anxiety and Depression in Patients with Rheumatoid Arthritis
Shmuel Tiosano ¹, Yarden Yavne ¹, Abdulla Watad ², Pnina Langevitz ³, Merav Lidar ⁴, Joy Feld ⁵, Moshe Tishler ⁶, Suhail Aamar ⁷, Ori Elkayam ⁸, Alexandra Balbir-Gurman ⁹, Yair Molad ¹⁰, Sharon Ehrlich ¹¹, Daniela Amital ¹² and Howard AMITAL¹, ¹Department of Medicine B, Ramat-Gan, Israel, ²Department of Medicine “B”, Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Ramat-Gan, Israel, ³Rhematology Unit, Ramat-Gan, Israel, ⁴Rheumatology Unit Sheba Medical Center, Ramat Gan, Israel, ⁵Carmel Hospital, Haifa, Israel, ⁶5Internal Department B, Assaf Harofeh Medical Center, Zrifin, Israel, Zrifin, Israel, ⁷Rheumatology Unit, Hadassah Mount Scopus Medical Center, Jeursalem, Israel, Jerusalem, Israel, ⁸Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁹Rambam Medical Center, Haifa, Israel, ¹⁰Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, HaMerkaz, Israel, ¹¹Roche Pharmaceuticals (Israel) Ltd., Hod HaSharon, Israel., Hod-Hashaon, Israel, ¹²Ness Ziona Beer-Yaacov Mental Health Center,, Beer-Yaakov, Israel
Background/Purpose: Mood disorders, such as anxiety and depression are extremely prevalent amongst patients with rheumatoid arthritis (RA). In this study we sought to assess the…
Abstract Number: 1368 • 2019 ACR/ARP Annual Meeting
One Size Fits All : Replacing ESR by γGT in DAS28 Calculation Permits a Dual Evaluation of Joint Activity Together with Cardiovascular Risk
Hélène Vergneault ¹, Eloïse Vandebeuque ², Veronica Codullo ¹, Yannick Allanore ³ and Jérôme Avouac¹, ¹Cochin Hospital, Paris, France, ²Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ³Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: Patients with rheumatoid arthritis (RA) experience premature mortality that is largely due to cardiovascular disease (CVD). Ample evidence suggests that elevated γGT activity is…
Abstract Number: 1395 • 2019 ACR/ARP Annual Meeting
Risk of Immunization to Rituximab in Systemic Autoimmune Diseases and Rheumatoid Arthritis: Frequency and Risk Factors. Analysis of the Efficacy of an Alternative Treatment by Ofatumumab
Alice Combier¹, Gaetane Nocturne ², Julien Henry ³, Rakiba Belkhir ¹, Stephan Pavy ⁴, Clotilde Le Tiec ⁵, Elise Descamps ⁴, Raphaele Seror ⁶ and Xavier Mariette ⁷, ¹Rheumatology Departement - Bicêtre Hospital, Paris, France, ²Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, ³Rheumatology Departement - Bicêtre Hospital, Paris, ⁴Rheumatology Departement - Bicètre Hospital, Paris, France, ⁵Pharmacy Departement - Bicètre Hospital, Paris, France, ⁶Hopitaux universitaires Paris Sud, Kremlin-Bicetre, France, ⁷Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: The most widely used B cell targeted therapies in auto-immune diseases (AID) is Rituximab (RTX), a murine chimeric monoclonal antibody. Among RTX’s side effects,…
Abstract Number: 1431 • 2019 ACR/ARP Annual Meeting
Real-Life Golimumab Persistence in Patients with Chronic Inflammatory Rheumatic Disease: Results of the GO PRACTICE Study
René-Marc Flipo¹, Florence Tubach ², Jean Ouaniche ³, Philippe Goupille ⁴, Eric Lespessailles ⁵, Najat Gouyette ⁶, Naoual Harid ⁷, Saannya Sequiera ⁸, Philippe Bertin ⁹ and Bruno Fautrel ¹⁰, ¹Roger Salengro University-Hospital, Lille , France, Lille, France, ²Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, ³Private Practice , Toulon, France, Toulon, France, ⁴Tours University-Hospital, Tours, France, Tours, France, ⁵Orléans Regional Hospitals, Orléans ,France, Orléans, France, ⁶MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, ⁷MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, ⁸ClinSearch ,Malakoff, France, Malakoff, Ile-de-France, France, ⁹Limoges University-Hospital , Limoges, France, Limoges, France, ¹⁰Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: The GO PRACTICE study was initiated following a demand by the French Health Authorities for long-term data on the real-life use of golimumab (GLM)…
Abstract Number: 1882 • 2019 ACR/ARP Annual Meeting
Anti-CCP Antibody and Pain Sensitization in Rheumatoid Arthritis
Yoon Mun¹, Tuhina Neogi ², Jing Song ³, Dorothy Dunlop ¹, Andrew Heisler ¹, Marcy Bolster ⁴, Clifton Bingham ⁵, Wendy Marder ⁶, Alyssa Wohlfahrt ⁷ and Yvonne Lee ⁸, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Boston University School of Medicine, Boston, MA, ³Northwestern University Feinberg School of Medicine, Worthington, OH, ⁴Massachusetts General Hospital, Boston, MA, ⁵Johns Hopkins University, Baltimore, ⁶Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, ⁷Brigham and Woman's Hospital, Boston, MA, ⁸Northwestern University Feinberg School of Medicine, Chicago
Background/Purpose: Many patients with RA report persistent pain in the absence of clinically appreciable inflammation. In a mouse model of inflammatory arthritis, mice injected with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].